HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Pharmacoresistance

Pharmacoresistance, a significant challenge in biopharmaceutics, refers to the reduced responsiveness of patients to therapeutic treatments over time. This phenomenon particularly impacts the efficacy of biopharmaceuticals, including protein-based drugs and monoclonal antibodies. The complexity of biological systems often leads to diverse mechanisms underlying pharmacoresistance, such as alterations in drug targets, impaired drug transport, or immune responses.

In the realm of biopharmaceutics, understanding and addressing pharmacoresistance is crucial for optimizing treatment outcomes. Researchers and pharmaceutical developers strive to unravel the underlying molecular mechanisms, employing innovative strategies to overcome resistance and enhance the therapeutic effectiveness of biopharmaceuticals. This may involve the design of novel drug delivery systems, combination therapies, or the development of next-generation biopharmaceuticals with improved resistance profiles.

The study and mitigation of pharmacoresistance in biopharmaceutics underscore the continuous evolution of strategies to ensure the sustained efficacy of these advanced therapeutic agents, contributing to the advancement of personalized and more effective healthcare solutions.

Committee Members
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami Miller School of Medicine, United States
Speaker at Drug Delivery Events -  Andreas M Papas

Andreas M Papas

Antares Health Products, United States
Speaker at Drug Delivery Events - Sergey Suchkov

Sergey Suchkov

The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation

Submit your abstract Today

Watsapp